Marijuana Rx Corporation
(888)453-3339

HIV / AIDS Marijuana References

HIV / AIDS Marijuana Treatment References

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139:258–266. [PubMed]
2. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25. [PubMed]
3. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–521. [PubMed]
4. ElSohly MA, deWit H, Wachtel SR, Feng S, Murphy TP. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol. 2001;25:565–571.[PubMed]
5. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med. 2010;362:1453–1457.[PubMed]
6. Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, et al. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Prev Med. 1985;14:81–91. [PubMed]
7. Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, et al. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med. 1988;18:8–15. [PubMed]
8. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, et al. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol. 2002;42:82S–89S. [PubMed]
9. Molina PE, Winsauer P, Zhang P, Walker E, Birke L, et al. Cannabinoid Administration Attenuates the Progression of Simian Immunodeficiency Virus. AIDS Res Hum Retroviruses 2011 [PMC free article][PubMed]
10. Demuth DG, Molleman A. Cannabinoid signalling. Life Sci. 2006;78:549–563. [PubMed]
11. Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 14; 2010;5(1):e8688. [PMC free article] [PubMed]
12. Borner C, Hollt V, Sebald W, Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol. 2007;81:336–343. [PubMed]
13. Klein TW, Newton CA. Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol. 2007;601:395–413. [PubMed]
14. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492–497. [PubMed]
15. Downer EJ, Clifford E, Gran B, Nel HJ, Fallon PG, et al. Identification of the Synthetic Cannabinoid R(+)WIN55,212-2 as a Novel Regulator of IFN Regulatory Factor 3 Activation and IFN-{beta} Expression: RELEVANCE TO THERAPEUTIC EFFECTS IN MODELS OF MULTIPLE SCLEROSIS. J Biol Chem. 2011;286:10316–10328. [PMC free article] [PubMed]
16. Ghosh S, Preet A, Groopman JE, Ganju RK. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol. 2006;43:2169–2179. [PubMed]
17. Pereira JP, An J, Xu Y, Huang Y, Cyster JG. Cannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids. Nat Immunol. 2009;10:403–411. [PMC free article] [PubMed]
18. Jiang S, Zagozdzon R, Jorda MA, Parmar K, Fu Y, et al. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. J Biol Chem. 2010;285:35471–35478. [PMC free article] [PubMed]Retracted
19. Yoder A, Yu D, Dong L, Iyer SR, Xu X, et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell. 2008;134:782–792. [PMC free article][PubMed]
20. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proc Natl Acad Sci U S A. 2010;107:16934–16939. [PMC free article] [PubMed]
21. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, et al. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007;110:4161–4164. [PubMed]
22. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997;94:1925–1930. [PMC free article] [PubMed]
23. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med. 1997;185:621–628. [PMC free article][PubMed]
24. Fenyo EM. HIV-1 biological phenotype varies with severity of infection across HIV-1 genetic subtypes. Antibiot Chemother. 1996;48:49–55. [PubMed]
25. Blaak H, van’t Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, et al. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A. 2000;97:1269–1274. [PMC free article][PubMed]
26. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity. 2001;15:671–682. [PubMed]
27. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61:213–222. [PubMed]
28. Hur EM, Kim KT. G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity. Cell Signal. 2002;14:397–405. [PubMed]
29. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997;186:1395–1400. [PMC free article] [PubMed]
30. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657–700. [PubMed]
31. Vila-Coro AJ, Mellado M, Martin de Ana A, Lucas P, del Real G, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A. 2000;97:3388–3393.[PMC free article] [PubMed]
32. Rodriguez-Frade JM, del Real G, Serrano A, Hernanz-Falcon P, Soriano SF, et al. Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J. 2004;23:66–76. [PMC free article] [PubMed]
33. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol. 2007;81:12582–12595. [PMC free article] [PubMed]
34. Hubner W, McNerney GP, Chen P, Dale BM, Gordon RE, et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science. 2009;323:1743–1747. [PMC free article][PubMed]
35. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999;10:661–671. [PubMed]
36. O’Brien WA, Koyanagi Y, Namazie A, Zhao JQ, Diagne A, et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature. 1990;348:69–73. [PubMed]
37. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002;20:1151–1154. [PubMed]
38. Gomes I, Filipovska J, Devi LA. Opioid receptor oligomerization. Detection and functional characterization of interacting receptors. Methods Mol Med. 2003;84:157–183. [PubMed]
39. Huffman JW. Cannabimimetic indoles, pyrroles and indenes. Curr Med Chem. 1999;6:705–720.[PubMed]
40. Lovinger DM. Presynaptic Modulation by Endocannabinoids. Springer, Berlin 2008 [PubMed]
41. Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, et al. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol. 2007;2:178–183. [PubMed]
42. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165:373–380. [PubMed]
43. Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol. 2000;164:6461–6466. [PubMed]
44. Wu Y, Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog. 2009;5:e1000520. [PMC free article] [PubMed]
45. Bukrinsky M. How to engage Cofilin. Retrovirology. 2008;5:85. [PMC free article] [PubMed]
46. Wu Y, Yoder A, Yu D, Wang W, Liu J, et al. Cofilin activation in peripheral CD4 T cells of HIV-1 infected patients: a pilot study. Retrovirology. 2008;5:95. [PMC free article] [PubMed]
47. Vorster PJ, Guo J, Yoder A, Wang W, Zheng Y, et al. LIM Kinase 1 Modulates Cortical Actin and CXCR4 Cycling and Is Activated by HIV-1 to Initiate Viral Infection. J Biol Chem. 2011;286:12554–12564. [PMC free article] [PubMed]
48. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol. 1993;67:2182–2190. [PMC free article][PubMed]
49. Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest. 2004;114:605–610.[PMC free article] [PubMed]
50. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004;199:283–293. [PMC free article] [PubMed]
51. Vasiliver-Shamis G, Tuen M, Wu TW, Starr T, Cameron TO, et al. Human immunodeficiency virus type 1 envelope gp120 induces a stop signal and virological synapse formation in noninfected CD4+ T cells. J Virol. 2008;82:9445–9457. [PMC free article] [PubMed]
52. Hubner W, Chen P, Del Portillo A, Liu Y, Gordon RE, et al. Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1. J Virol. 2007;81:12596–12607. [PMC free article][PubMed]
53. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, et al. The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol. 2004;11:672–675. [PubMed]
54. Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS. 2009;4:96–103.[PMC free article] [PubMed]
55. Simmons G, Reeves JD, Hibbitts S, Stine JT, Gray PW, et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev. 2000;177:112–126. [PubMed]
56. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 1997;186:139–146. [PMC free article] [PubMed]
57. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2011;330:1066–1071. [PMC free article][PubMed]
58. Yu D, Wang W, Yoder A, Spear M, Wu Y. The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 2009;5:e1000633. [PMC free article][PubMed]
59. Moreira FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009;23:133–144. [PubMed]

EQUAL MEDICINE ORGANIZATION - Marijuana ALS Amyotrophic Lateral Sclerosis Treatment cures medical marijuana thc cannabis cbd